Medeon Biodesign - Asset Resilience Ratio
Medeon Biodesign (6499) has an Asset Resilience Ratio of 7.38% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Medeon Biodesign balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Medeon Biodesign's Asset Resilience Ratio has changed over time. See Medeon Biodesign (6499) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Medeon Biodesign's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Medeon Biodesign (6499) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$104.62 Million | 7.38% |
| Total Liquid Assets | NT$104.62 Million | 7.38% |
Asset Resilience Insights
- Limited Liquidity: Medeon Biodesign maintains only 7.38% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Medeon Biodesign Industry Peers by Asset Resilience Ratio
Compare Medeon Biodesign's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 18.11% |
|
SWS Hemodialysis Care Co. Ltd. A
SHG:688410 |
Medical Instruments & Supplies | 38.45% |
|
Hangzhou Alltest Biotech Co. Ltd. A
SHG:688606 |
Medical Instruments & Supplies | 11.88% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 46.84% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 3.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Trajan Group Holdings Ltd
AU:TRJ |
Medical Instruments & Supplies | 0.29% |
Annual Asset Resilience Ratio for Medeon Biodesign (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Medeon Biodesign.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 36.95% | NT$693.84 Million ≈ $21.86 Million |
NT$1.88 Billion ≈ $59.16 Million |
+4.04pp |
| 2023-12-31 | 32.91% | NT$904.03 Million ≈ $28.48 Million |
NT$2.75 Billion ≈ $86.55 Million |
+6.59pp |
| 2022-12-31 | 26.32% | NT$1.06 Billion ≈ $33.50 Million |
NT$4.04 Billion ≈ $127.28 Million |
-10.67pp |
| 2021-12-31 | 36.99% | NT$1.61 Billion ≈ $50.87 Million |
NT$4.36 Billion ≈ $137.51 Million |
+5.07pp |
| 2020-12-31 | 31.92% | NT$1.06 Billion ≈ $33.34 Million |
NT$3.31 Billion ≈ $104.42 Million |
-20.85pp |
| 2019-12-31 | 52.77% | NT$1.33 Billion ≈ $41.85 Million |
NT$2.52 Billion ≈ $79.30 Million |
-1.65pp |
| 2018-12-31 | 54.42% | NT$1.06 Billion ≈ $33.39 Million |
NT$1.95 Billion ≈ $61.35 Million |
+5.56pp |
| 2017-12-31 | 48.86% | NT$800.44 Million ≈ $25.22 Million |
NT$1.64 Billion ≈ $51.61 Million |
-- |
About Medeon Biodesign
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular g… Read more